ArticleImmunity, inflammation and disease2026
Widespread SARS-CoV-2 Transmission Despite Limited Reported Cases and Clinical Disease: Exploring the Role of Pre-Existing Humoral Immunity to SARS-CoV-2 in Eastern Sierra Leone.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Widespread SARS-CoV-2 Transmission Despite Limited Reported Cases and Clinical Disease: Exploring the Role of Pre-Existing Humoral Immunity to SARS-CoV-2 in Eastern Sierra Leone.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSince December 2019, SARS-CoV-2 has infected over 700 million people and caused > 7 million deaths. While much of the global north was severely affected, sub-Saharan Africa was relatively spared. Possible reasons include a younger population, fewer comorbidities, and pre-existing immunity. Here, we expand on previous work through a cohort of 306 subjects, with samples drawn pre-pandemic, intra-pandemic, and post-vaccination.
methodsWe assessed antibody reactivity to seasonal coronaviruses, emerging coronaviruses, and SARS-CoV-2 spike (S), nucleoprotein (N), and receptor binding domain (RBD) proteins in a longitudinal cohort. Antibody neutralization was measured using a pseudovirus neutralization assay.
resultsOur data show that 16%-20% of pre-pandemic samples had reactivity to SARS-CoV-2 N protein. Further, we noted relatively high reactivity to SARS-CoV-2 RBD (~31%), and low, but notable, seropositivity to SARS-CoV-2 S protein (3.3%-3.4%). We additionally found a significant jump in seropositivity to all SARS-CoV-2 proteins by March 2022 (intra-pandemic), and high levels of neutralization in the intra-pandemic samples compared to pre-pandemic samples. A boosting effect on SARS-CoV-2 Spike was observed after vaccination.
conclusionsWe report widespread circulation of SARS-CoV-2 in eastern Sierra Leone by March 2022 despite low national reporting. Furthermore, we provide evidence of pre-existing humoral immunity to SARS-CoV-2 as compared to US controls. This may have resulted in less severe disease, less COVID-19 testing and the apparent lack of clinical cases. Finally, we show boosting of SARS-CoV-2 Spike following vaccination. Studies comparing HLA type between symptomatic and asymptomatic cases are being planned. Studies to better characterize cellular immunity from pre-pandemic timepoints should also be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.